Heart Failure With Preserved Ejection FractionHFpEFNCT07413198
BOOST: Blended Onsite and Offsite Structured Exercise Training and Coaching
A study testing multi-domain behavioral, coaching, and exercise protocol in people with Heart Failure With Preserved Ejection Fraction, run by Wake Forest University Health Sciences at 1 site in United States.
Trial summary
Heart failure with preserved ejection fraction (HFpEF) represents a major public health burden that is both growing rapidly and has few effective therapies. Supervised exercise training (SET) is one of the few effective therapies for older patients with HFpEF, but is currently constrained by cost, resource… Read more about this study
- Who is it for?
- Ages 55 years and older
- Conditions the study is for
- Heart Failure With Preserved Ejection Fraction
- What is being tested?
- multi-domain behavioral, coaching, and exercise protocol
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 14 participants
- Where
- 1 siteUnited States
- Study dates
- 5 May 2026to Mar 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 55 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Diagnosis of heart failure with signs and symptoms of heart failure and at least one of the following: Evidence of increased LV filling pressures at rest, exercise, or other provocations / Prior HF hospitalization / Elevated heart Failure with Preserved Ejection Fraction (H2FPEF) score or elevated Heart Failure Association-Pre-test, Echocardiography \& natriuretic peptide, Functional testing, Final etiology (HFA-PEFF) score
- Left ventricular ejection fraction ≥ 50%
- New York Heart Association (NYHA) functional class II-IV
- Age ≥ 55 years old
Who cannot join
- Significant change in cardiac medication or heart failure (HF) symptoms within 3 weeks prior to enrollment
- Hospitalization or urgent care visit for HF within 4 weeks prior to enrollment
- Acute coronary syndrome, stroke, transient ischemic attack; cardiac, carotid or other major Cardiac Vascular (CV) surgery; percutaneous coronary intervention (PCI) or carotid angioplasty, within 30 days prior to enrolment
- Uncontrolled hypertension
- Recent or debilitating stroke
- Severe pulmonary disease including chronic obstructive pulmonary disease (COPD)
Show all 16Show fewer
- Hemoglobin (Hgb) < 9.5 g/dL males and < 9 g/dL females within 30 days prior to enrollment
- Patients with a history of heart transplant or Left Ventricular Assist Device (LVAD), currently on the transplant list
- Significant, unrepaired cardiac valvular disease
- A non-cardiac medical condition with an estimated life expectancy of < 12 months
- Known pericardial constriction, genetic hypertrophic cardiomyopathy, or infiltrative cardiomyopathy including amyloid heart disease (amyloidosis)
- Life-threatening or uncontrolled dysrhythmia, including symptomatic or sustained ventricular tachycardia and atrial fibrillation or flutter
- A treadmill exercise test revealing: ischemia; chest pain or leg claudication; exercise Systolic Blood Pressure > 240 mmHg, Diastolic Blood Pressure > 110 mmHg; unstable hemodynamics or rhythm; or unwilling or unable to complete adequate exercise test
- Already engaging in regular moderate to vigorous exercise conditioning defined as >30 minutes per day, ≥twice per week consistently during the previous 6 weeks
- Any condition that in the judgement of the investigator precludes participation in study or study procedures such as significant dementia, mobility impairment, uncontrolled psychiatric disease, etc.
- Inability to meet the expectations of the intervention (i.e., excessive distance from facility, work conflict with intervention)
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site, 1 recruiting
- Recruiting
Wake Forest University Health Sciences
Winston-Salem, North Carolina, 27157
Anthony E Peters, MD, 336-713-2278, Anthony.Peters@advocatehealth.org
Kimberly Kennedy, MS, 336.713.8567, Kimberly.Kennedy@Advocatehealth.org
About this study
Official title: A Novel, Group-mediated Exercise Intervention With Remote Activity Monitoring in Patients With Heart Failure With Preserved Ejection Fraction (HFpEF)
Heart failure with preserved ejection fraction (HFpEF) represents a major public health burden that is both growing rapidly and has few effective therapies. Supervised exercise training (SET) is one of the few effective therapies for older patients with HFpEF, but is currently constrained by cost, resource limitations, and sub-optimal short and long-term clinical response. The objective is to develop and test novel strategies to augment the therapy of exercise training to optimize response and resource utilization in older patients with HFpEF.
Read the detailed description
The hypothesis is that enhancing Supervised exercise training (SET) with a group-mediated behavioral approach and remote activity-monitoring will enable more robust behavioral changes in physical activity at lower cost. To test this hypothesis, the study will recruit patients with Heart failure with preserved ejection fraction (HFpEF) and assign to 2 sequential groups/waves for trainer-guided, aerobic-based exercise and group counseling sessions, with iterative refinements between waves.
- Being tested
- multi-domain behavioral, coaching, and exercise protocol
- Keywords
- Heart failure, Supervised exercise training, Group-based exercise
- Medical subject headings
- Heart Failure
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
multi-domain behavioral, coaching, and exercise protocolBehavioural
Also called behavioral, coaching, and exercise
Group-mediated educational sessions, individual coaching contacts, group exercise sessions, and home-based self-guided exercise - Groups will engage in this iterative, trainer-guided, in-person, aerobic-based exercise and group counseling sessions approximately 2 times/week for 12 weeks.
| Study group | Role | What they receive |
|---|---|---|
| multi-domain behavioral, coaching, and exercise protocol | Experimental | A non-randomized, single-arm, iterative refinement pilot study. The study will recruit older patients with Heart Failure with Preserved Ejection Fraction (HFpEF) and assign them to 2 sequential groups/waves for trainer-guided, aerobic-based exercise and group counseling sessions, with iterative refinements between waves. Receives: Behavioral: multi-domain behavioral, coaching, and exercise protocol |
What is being measured
The primary outcome is the main question the study is designed to answer.
Exercise self-efficacy scales Scores
Total score is calculated by summing the responses to each question. This scale has a range of total scores from 0-90. A higher score indicates higher self-efficacy for exercise.
Measured: Baseline
Exercise self-efficacy scales Scores
Total score is calculated by summing the responses to each question. This scale has a range of total scores from 0-90. A higher score indicates higher self-efficacy for exercise.
Measured: Week 4
Exercise self-efficacy scales Scores
Total score is calculated by summing the responses to each question. This scale has a range of total scores from 0-90. A higher score indicates higher self-efficacy for exercise.
Measured: Week 12
Exercise Benefits/Barriers Scale Score
Evaluates how participants determine benefits of and barriers to participating in exercise.
Measured: Baseline
Exercise Benefits/Barriers Scale Score
Evaluates how participants determine benefits of and barriers to participating in exercise.
Measured: Week 4
Exercise Benefits/Barriers Scale Score
Evaluates how participants determine benefits of and barriers to participating in exercise.
Measured: Week 12
Heart Failure quality-of-life assessment - Kansas City Cardiomyopathy Questionnaire (KCCQ) Scores
scores from 0-100, where higher scores indicate better health
Measured: Baseline
Heart Failure quality-of-life assessment - Kansas City Cardiomyopathy Questionnaire (KCCQ) Scores
scores from 0-100, where higher scores indicate better health
Measured: Week 4
Heart Failure quality-of-life assessment - Kansas City Cardiomyopathy Questionnaire (KCCQ) Scores
scores from 0-100, where higher scores indicate better health
Measured: Week 12
Number of daily steps by accelerometer
Number of daily steps recorded for 1 week
Measured: Baseline
Number of daily steps by accelerometer
Number of daily steps recorded for 1 week
Measured: Week 4
Number of daily steps by accelerometer
Number of daily steps recorded for 1 week
Measured: Week 12
6-minute walk distance
measures functional capacity by the distance walked in 6 minutes, indicating disease severity, prognosis, and treatment response, especially in cardiopulmonary conditions like COPD or heart failure shorter distances (e.g., <350m) often signaling higher mortality risk, while significant changes (e.g., >50m) suggest clinical improvement or decline, though interpretation always needs clinical context and comparison to age/gender norms.
Measured: Baseline
6-minute walk distance
measures functional capacity by the distance walked in 6 minutes, indicating disease severity, prognosis, and treatment response, especially in cardiopulmonary conditions like COPD or heart failure shorter distances (e.g., <350m) often signaling higher mortality risk, while significant changes (e.g., >50m) suggest clinical improvement or decline, though interpretation always needs clinical context and comparison to age/gender norms.
Measured: Week 4
6-minute walk distance
measures functional capacity by the distance walked in 6 minutes, indicating disease severity, prognosis, and treatment response, especially in cardiopulmonary conditions like COPD or heart failure shorter distances (e.g., <350m) often signaling higher mortality risk, while significant changes (e.g., >50m) suggest clinical improvement or decline, though interpretation always needs clinical context and comparison to age/gender norms.
Measured: Week 12
The Short Physical Performance Battery (SPPB) Score
The SPPB is a measure of physical function that incorporates three components: usual gait speed measured over 4 meters, timed repeated chair rise, and standing balance with progressively narrow base of support. Each component is scored on a 0-4 scale and then summed to provide an overall score range of 0-12 - scores ranging from 0 (worst) to 12 (best).
Measured: Baseline
The Short Physical Performance Battery (SPPB) Score
The SPPB is a measure of physical function that incorporates three components: usual gait speed measured over 4 meters, timed repeated chair rise, and standing balance with progressively narrow base of support. Each component is scored on a 0-4 scale and then summed to provide an overall score range of 0-12 - scores ranging from 0 (worst) to 12 (best).
Measured: Week 4
The Short Physical Performance Battery (SPPB) Score
The SPPB is a measure of physical function that incorporates three components: usual gait speed measured over 4 meters, timed repeated chair rise, and standing balance with progressively narrow base of support. Each component is scored on a 0-4 scale and then summed to provide an overall score range of 0-12 - scores ranging from 0 (worst) to 12 (best).
Measured: Week 12
Grip strength
Low handgrip strength, a key indicator in sarcopenia, is often defined as <28 kg for men and <18 kg for women (based on AWGS19) or even lower, depending on the study, such as <26 kg and <16 kg.
Measured: Baseline
Grip strength
Low handgrip strength, a key indicator in sarcopenia, is often defined as <28 kg for men and <18 kg for women (based on AWGS19) or even lower, depending on the study, such as <26 kg and <16 kg.
Measured: Week 4
Grip strength
Low handgrip strength, a key indicator in sarcopenia, is often defined as <28 kg for men and <18 kg for women (based on AWGS19) or even lower, depending on the study, such as <26 kg and <16 kg.
Measured: Week 12
Cardiopulmonary Exercise Testing (CPET)
Evaluates how your heart, lungs, and muscles work together during physical exertion, using a treadmill or bike while monitoring breathing (mask), heart activity (ECG), and vitals (blood pressure) to diagnose causes of shortness of breath, assess heart/lung conditions like heart failure or Chronic Obstructive Pulmonary Disease (COPD), and determine exercise capacity, offering a comprehensive view of cardiovascular and respiratory fitness.
Normal values typically range from 35 to 40 mL/kg/min for healthy middle-aged individuals, with variations based on age, sex, and training status.
Measured: Baseline
Cardiopulmonary Exercise Testing (CPET)
Evaluates how your heart, lungs, and muscles work together during physical exertion, using a treadmill or bike while monitoring breathing (mask), heart activity (ECG), and vitals (blood pressure) to diagnose causes of shortness of breath, assess heart/lung conditions like heart failure or Chronic Obstructive Pulmonary Disease (COPD), and determine exercise capacity, offering a comprehensive view of cardiovascular and respiratory fitness.
Normal values typically range from 35 to 40 mL/kg/min for healthy middle-aged individuals, with variations based on age, sex, and training status.
Measured: Week 12
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted17 Feb 2026
- Study start5 May 2026
- Primary completionMar 2027 (estimated)
- Study completionMar 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Heart Failure With Preserved Ejection FractionStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Supportive care
- Allocation
- Not applicable
- Intervention model
- Single group
- Model description
- older patients with Heart Failure with Preserved Ejection Fraction (HFpEF) will be assigned to 2 sequential groups/waves for trainer-guided, aerobic-based exercise and group counseling sessions, with iterative refinements between waves.
- Masking
- None (open label)
- Enrolment
- 14 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Wake Forest University Health Sciences
- Sponsor type
- University, hospital or other
- Collaborators
- National Institute on Aging (NIA)
- Responsible party
- Sponsor
- Investigators
- Anthony E Peters, MD, Principal investigator, Wake Forest University Health Sciences
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07413198
- Sponsor's protocol ID
- IRB00142040
- Other IDs
- 00000132, P30AG021332
- Acronym
- HFpEF
- Status last verified
- May 2026
- First submitted
- 9 Feb 2026
- Last updated
- 26 May 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 26 May 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Novel, Group-mediated Exercise Intervention With Remote Activity Monitoring in Patients With Heart Failure With Preserved Ejection Fraction (HFpEF)
- ClinicalTrials.gov ID
- NCT07413198
- Acronym / sponsor ID
- HFpEF / IRB00142040
- Keywords
- Heart failure, Supervised exercise training, Group-based exercise
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 14 participants (estimated)
- Lead sponsor
- Wake Forest University Health SciencesUniversity, hospital or other
- Collaborators
- National Institute on Aging (NIA)
- Study start
- 5 May 2026 (actual)
- Primary completion
- Mar 2027 (estimated)
- Study completion
- Mar 2027 (estimated)
- First posted
- 17 Feb 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Heart failure with preserved ejection fraction (HFpEF) represents a major public health burden that is both growing rapidly and has few effective therapies. Supervised exercise training (SET) is one of the few effective therapies for older patients with HFpEF, but is currently constrained by cost, resource limitations, and sub-optimal short and long-term clinical response. The objective is to develop and test novel strategies to augment the therapy of exercise training to optimize response and resource utilization in older patients with HFpEF.
Detailed description
The hypothesis is that enhancing Supervised exercise training (SET) with a group-mediated behavioral approach and remote activity-monitoring will enable more robust behavioral changes in physical activity at lower cost. To test this hypothesis, the study will recruit patients with Heart failure with preserved ejection fraction (HFpEF) and assign to 2 sequential groups/waves for trainer-guided, aerobic-based exercise and group counseling sessions, with iterative refinements between waves.
Study design
- Primary purpose
- Supportive care
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
- Model description
- older patients with Heart Failure with Preserved Ejection Fraction (HFpEF) will be assigned to 2 sequential groups/waves for trainer-guided, aerobic-based exercise and group counseling sessions, with iterative refinements between waves.
| Arm | Type | Receives |
|---|---|---|
| multi-domain behavioral, coaching, and exercise protocol | Experimental | Behavioral: multi-domain behavioral, coaching, and exercise protocolA non-randomized, single-arm, iterative refinement pilot study. The study will recruit older patients with Heart Failure with Preserved Ejection Fraction (HFpEF) and assign them to 2 sequential groups/waves for trainer-guided, aerobic-based exercise and group counseling sessions, with iterative refinements between waves. |
Who may qualify
- Ages
- 55 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Diagnosis of heart failure with signs and symptoms of heart failure and at least one of the following: Evidence of increased LV filling pressures at rest, exercise, or other provocations / Prior HF hospitalization / Elevated heart Failure with Preserved Ejection Fraction (H2FPEF) score or elevated Heart Failure Association-Pre-test, Echocardiography \& natriuretic peptide, Functional testing, Final etiology (HFA-PEFF) score
- Left ventricular ejection fraction ≥ 50%
- New York Heart Association (NYHA) functional class II-IV
- Age ≥ 55 years old
Key exclusion criteria (16 listed)
- Significant change in cardiac medication or heart failure (HF) symptoms within 3 weeks prior to enrollment
- Hospitalization or urgent care visit for HF within 4 weeks prior to enrollment
- Acute coronary syndrome, stroke, transient ischemic attack; cardiac, carotid or other major Cardiac Vascular (CV) surgery; percutaneous coronary intervention (PCI) or carotid angioplasty, within 30 days prior to enrolment
- Uncontrolled hypertension
- Recent or debilitating stroke
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| multi-domain behavioral, coaching, and exercise protocolAlso: behavioral, coaching, and exerciseGroup-mediated educational sessions, individual coaching contacts, group exercise sessions, and home-based self-guided exercise - Groups will engage in this iterative, trainer-guided, in-person, aerobic-based exercise and group counseling sessions approximately 2 times/week for 12 weeks. | Behavioural | multi-domain behavioral, coaching, and exercise protocol |
Primary outcome
Exercise self-efficacy scales Scores
Time frame: Baseline
Total score is calculated by summing the responses to each question. This scale has a range of total scores from 0-90. A higher score indicates higher self-efficacy for exercise.
Exercise self-efficacy scales Scores
Time frame: Week 4
Total score is calculated by summing the responses to each question. This scale has a range of total scores from 0-90. A higher score indicates higher self-efficacy for exercise.
Exercise self-efficacy scales Scores
Time frame: Week 12
Total score is calculated by summing the responses to each question. This scale has a range of total scores from 0-90. A higher score indicates higher self-efficacy for exercise.
Exercise Benefits/Barriers Scale Score
Time frame: Baseline
Evaluates how participants determine benefits of and barriers to participating in exercise.
Exercise Benefits/Barriers Scale Score
Time frame: Week 4
Evaluates how participants determine benefits of and barriers to participating in exercise.
Exercise Benefits/Barriers Scale Score
Time frame: Week 12
Evaluates how participants determine benefits of and barriers to participating in exercise.
Heart Failure quality-of-life assessment - Kansas City Cardiomyopathy Questionnaire (KCCQ) Scores
Time frame: Baseline
scores from 0-100, where higher scores indicate better health
Heart Failure quality-of-life assessment - Kansas City Cardiomyopathy Questionnaire (KCCQ) Scores
Time frame: Week 4
scores from 0-100, where higher scores indicate better health
Heart Failure quality-of-life assessment - Kansas City Cardiomyopathy Questionnaire (KCCQ) Scores
Time frame: Week 12
scores from 0-100, where higher scores indicate better health
Number of daily steps by accelerometer
Time frame: Baseline
Number of daily steps recorded for 1 week
Number of daily steps by accelerometer
Time frame: Week 4
Number of daily steps recorded for 1 week
Number of daily steps by accelerometer
Time frame: Week 12
Number of daily steps recorded for 1 week
6-minute walk distance
Time frame: Baseline
measures functional capacity by the distance walked in 6 minutes, indicating disease severity, prognosis, and treatment response, especially in cardiopulmonary conditions like COPD or heart failure shorter distances (e.g., <350m) often signaling higher mortality risk, while significant changes (e.g., >50m) suggest clinical improvement or decline, though interpretation always needs clinical context and comparison to age/gender norms.
6-minute walk distance
Time frame: Week 4
measures functional capacity by the distance walked in 6 minutes, indicating disease severity, prognosis, and treatment response, especially in cardiopulmonary conditions like COPD or heart failure shorter distances (e.g., <350m) often signaling higher mortality risk, while significant changes (e.g., >50m) suggest clinical improvement or decline, though interpretation always needs clinical context and comparison to age/gender norms.
6-minute walk distance
Time frame: Week 12
measures functional capacity by the distance walked in 6 minutes, indicating disease severity, prognosis, and treatment response, especially in cardiopulmonary conditions like COPD or heart failure shorter distances (e.g., <350m) often signaling higher mortality risk, while significant changes (e.g., >50m) suggest clinical improvement or decline, though interpretation always needs clinical context and comparison to age/gender norms.
The Short Physical Performance Battery (SPPB) Score
Time frame: Baseline
The SPPB is a measure of physical function that incorporates three components: usual gait speed measured over 4 meters, timed repeated chair rise, and standing balance with progressively narrow base of support. Each component is scored on a 0-4 scale and then summed to provide an overall score range of 0-12 - scores ranging from 0 (worst) to 12 (best).
The Short Physical Performance Battery (SPPB) Score
Time frame: Week 4
The SPPB is a measure of physical function that incorporates three components: usual gait speed measured over 4 meters, timed repeated chair rise, and standing balance with progressively narrow base of support. Each component is scored on a 0-4 scale and then summed to provide an overall score range of 0-12 - scores ranging from 0 (worst) to 12 (best).
The Short Physical Performance Battery (SPPB) Score
Time frame: Week 12
The SPPB is a measure of physical function that incorporates three components: usual gait speed measured over 4 meters, timed repeated chair rise, and standing balance with progressively narrow base of support. Each component is scored on a 0-4 scale and then summed to provide an overall score range of 0-12 - scores ranging from 0 (worst) to 12 (best).
Grip strength
Time frame: Baseline
Low handgrip strength, a key indicator in sarcopenia, is often defined as <28 kg for men and <18 kg for women (based on AWGS19) or even lower, depending on the study, such as <26 kg and <16 kg.
Grip strength
Time frame: Week 4
Low handgrip strength, a key indicator in sarcopenia, is often defined as <28 kg for men and <18 kg for women (based on AWGS19) or even lower, depending on the study, such as <26 kg and <16 kg.
Grip strength
Time frame: Week 12
Low handgrip strength, a key indicator in sarcopenia, is often defined as <28 kg for men and <18 kg for women (based on AWGS19) or even lower, depending on the study, such as <26 kg and <16 kg.
Cardiopulmonary Exercise Testing (CPET)
Time frame: Baseline
Evaluates how your heart, lungs, and muscles work together during physical exertion, using a treadmill or bike while monitoring breathing (mask), heart activity (ECG), and vitals (blood pressure) to diagnose causes of shortness of breath, assess heart/lung conditions like heart failure or Chronic Obstructive Pulmonary Disease (COPD), and determine exercise capacity, offering a comprehensive view of cardiovascular and respiratory fitness. Normal values typically range from 35 to 40 mL/kg/min for healthy middle-aged individuals, with variations based on age, sex, and training status.
Cardiopulmonary Exercise Testing (CPET)
Time frame: Week 12
Evaluates how your heart, lungs, and muscles work together during physical exertion, using a treadmill or bike while monitoring breathing (mask), heart activity (ECG), and vitals (blood pressure) to diagnose causes of shortness of breath, assess heart/lung conditions like heart failure or Chronic Obstructive Pulmonary Disease (COPD), and determine exercise capacity, offering a comprehensive view of cardiovascular and respiratory fitness. Normal values typically range from 35 to 40 mL/kg/min for healthy middle-aged individuals, with variations based on age, sex, and training status.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 26 May 2026.
- Individual participant dataSharing planned: No
Related trials for Heart Failure With Preserved Ejection Fraction
RecruitingPhase 3
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
Heart Failure With Preserved Ejection Fraction, Heart Failure With Mildly Reduced Ejection Fraction
Recruiting
PrEcision Pacing in HFpEF: the PEP-HFpEF Trial
Heart Failure and Preserved Ejection Fraction, Heart Failure New York Heart Association Class III
Active, not recruiting
Fast Induced Remodeling in Heart Failure With Preserved Ejection Fraction
Heart Failure With Preserved Ejection Fraction, Concentric Hypertrophy
Recruiting
Leg Heat Therapy in Heart Failure With Preserved Ejection Fraction
Heart Failure With Preserved Ejection Fraction
Not yet recruiting
Virtual Human Twins as Tools for Personalized Clinical Care in Heart Failure With Preserved Ejection Fraction: a Pilot Study
Heart Failure
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Anthony E Peters, MD principal investigator
Wake Forest University Health Sciences
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing multi-domain behavioral, coaching, and exercise protocol in people with Heart Failure With Preserved Ejection Fraction, run by Wake Forest University Health Sciences at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 16 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 26 May 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Anthony E Peters, MD (336-713-2278, Anthony.Peters@advocatehealth.org), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Exercise self-efficacy scales Scores (time frame: Baseline). The study lists 23 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 May 2026.